wxbcvanpu
2021-02-03
什么意思呢
ROCE Insights For Bionano Genomics
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":314045955,"tweetId":"314045955","gmtCreate":1612281975977,"gmtModify":1703759960180,"author":{"id":3566212400811103,"authorId":3566212400811103,"authorIdStr":"3566212400811103","name":"wxbcvanpu","avatar":"https://static.tigerbbs.com/4b24368ca481cf01f78abb3439ce4272","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>什么意思呢</p></body></html>","htmlText":"<html><head></head><body><p>什么意思呢</p></body></html>","text":"什么意思呢","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/314045955","repostId":2108398627,"repostType":2,"repost":{"id":"2108398627","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1612284397,"share":"https://www.laohu8.com/m/news/2108398627?lang=&edition=full","pubTime":"2021-02-03 00:46","market":"hk","language":"en","title":"ROCE Insights For Bionano Genomics","url":"https://stock-news.laohu8.com/highlight/detail?id=2108398627","media":"Benzinga","summary":"During Q3, Bionano Genomics's (NASDAQ:BNGO) reported sales totaled $2.20 million. Despite a 37.55% in earnings, the company posted a loss of $10.23 million. Bionano Genomics collected $1.18 million in revenue during Q2, but reported earnings showed a $7.43 million loss.","content":"<html><body><p>During Q3, <strong><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></strong>'s (NASDAQ:BNGO) reported sales totaled $2.20 million. Despite a 37.55% in earnings, the company posted a loss of $10.23 million. Bionano Genomics collected $1.18 million in revenue during Q2, but reported earnings showed a $7.43 million loss.</p>\n<h3>What Is ROCE?</h3>\n<p>Changes in earnings and sales indicate shifts in Bionano Genomics's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Bionano Genomics posted an ROCE of -0.7%.</p>\n<p>It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.</p>\n<p>Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.</p>\n<p>For Bionano Genomics, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.</p>\n<h3>Q3 Earnings Recap</h3>\n<p>Bionano Genomics reported Q3 earnings per share at $-0.08/share, which did not meet analyst predictions of $-0.05/share.</p>\n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ROCE Insights For Bionano Genomics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nROCE Insights For Bionano Genomics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-02-03 00:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>During Q3, <strong><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a></strong>'s (NASDAQ:BNGO) reported sales totaled $2.20 million. Despite a 37.55% in earnings, the company posted a loss of $10.23 million. Bionano Genomics collected $1.18 million in revenue during Q2, but reported earnings showed a $7.43 million loss.</p>\n<h3>What Is ROCE?</h3>\n<p>Changes in earnings and sales indicate shifts in Bionano Genomics's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Bionano Genomics posted an ROCE of -0.7%.</p>\n<p>It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.</p>\n<p>Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.</p>\n<p>For Bionano Genomics, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.</p>\n<h3>Q3 Earnings Recap</h3>\n<p>Bionano Genomics reported Q3 earnings per share at $-0.08/share, which did not meet analyst predictions of $-0.05/share.</p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"https://www.benzinga.com/node/19445351","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2108398627","content_text":"During Q3, Bionano Genomics's (NASDAQ:BNGO) reported sales totaled $2.20 million. Despite a 37.55% in earnings, the company posted a loss of $10.23 million. Bionano Genomics collected $1.18 million in revenue during Q2, but reported earnings showed a $7.43 million loss.\nWhat Is ROCE?\nChanges in earnings and sales indicate shifts in Bionano Genomics's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Bionano Genomics posted an ROCE of -0.7%.\nIt is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.\nReturn on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.\nFor Bionano Genomics, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.\nQ3 Earnings Recap\nBionano Genomics reported Q3 earnings per share at $-0.08/share, which did not meet analyst predictions of $-0.05/share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":516,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":10,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/314045955"}
精彩评论